We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Protein Form Linked to Huntington's Disease Identified

By LabMedica International staff writers
Posted on 16 Nov 2011
A protein called polyglutamine (polyQ) has been identified by immunological assays that predict in situ neurodegeneration in Huntington's disease. More...


A form of the protein that is linked to Huntington's disease influences the timing and severity of its symptoms, offering new avenues for treating not only this disease, but also a variety of similar conditions.

Scientists at the Gladstone Institute of Neurological Disease, (San Francisco, CA, USA) screened numerous antibodies that each bind uniquely to one type of misfolded huntingtin protein (Htt) in order to identify and tag each type. These antibodies acted as molecular tracking devices that are monitored with an automated microscope and specialized software. Experiments revealed that one of the antibodies, 3B5H10, bound to a form of Htt closely linked to neuron death and, therefore, disease progression.

Huntington's is an ultimately fatal disease that affects more than a quarter of a million people nationwide, is caused by mutations in the gene that creates the huntingtin, or Htt, protein. As the mutated gene produces Htt, a segment of the protein called polyglutamine is mistakenly expanded, distorting Htt's natural shape and function. As a result, the misfolded protein malfunctions and can be toxic.

Neuronal death is the key to the development of Huntington's symptoms, including erratic behavior, memory loss, and involuntary muscle movement. This study underscored the value of the cross-disciplinary work done at Gladstone while revealing techniques that scientists anywhere can apply to conditions involving misfolded proteins, such as Alzheimer's disease and type 1 diabetes.

Steven Finkbeiner, MD, PhD, a senior investigator at the Gladstone Institute said, "Effective treatments for diseases such as Huntington's and Alzheimer's have been slow to develop. We hope that our newfound understanding of precisely which misfolded proteins contribute to disease symptoms will speed up drug development for sufferers.” The study was published October 30, 2011, in the journal Nature Chemical Biology.

Related Links:
Gladstone Institute of Neurological Disease




New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Microscope
dIFine
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The Volition Nu.Q nucleosome assay runs on the IDS i10 automated analyzer platform (Photo courtesy of VolitionRx)

Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes

Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. Traditional testing methods can be slow, expensive,... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.